New Research on GLP-1 Drugs and Cancer Protection

Recent findings indicate that well-known GLP-1 medications, often prescribed for weight management and diabetes, might also help reduce the risk of various cancers.

At the American Society of Clinical Oncology meeting in Chicago, over two dozen studies were shared, revealing that patients using these medications had a lower risk of developing cancer, better outcomes, and an improved response to certain treatments compared to those who weren’t on GLP-1 drugs.

The research involved both clinical records and actual data from patients taking medications like Novo Nordisk’s Wegovy or Ozempic, and Eli Lilly’s Mounjaro or Zepbound, along with earlier GLP-1 options.

Although these studies didn’t specifically aim to explain how GLP-1s might affect cancer treatment, researchers think that by decreasing inflammation and managing insulin levels, these drugs might positively influence tumor biology.

Dr. Elizabeth Susan McDonald from the University of Pennsylvania noted the significance of chronic inflammation in cancer development. She presented findings from a large study involving 110,000 women, which showed that those taking GLP-1 medications had up to a 35% lower likelihood of developing breast cancer compared to those who didn’t use them.

Obesity has long been recognized as a risk factor for specific cancers, so it seems that the anti-inflammatory properties of GLP-1s could play a key role in preventing cancer, according to McDonald.

Widespread Benefits Across Different Cancers

GLP-1 drugs encompass several medications, including semaglutide (found in Wegovy, Ozempic, and Rybelsus) and tirzepatide (found in Mounjaro and Zepbound), among others.

A particularly notable study involving over 12,000 patients indicated that the use of GLP-1 drugs was linked to significantly reduced chances of cancer metastasizing, especially in lung, breast, colorectal, and liver cancers.

Patients with these cancers who were on medications like liraglutide and tirzepatide faced a 38% to 50% lower risk of disease progression compared to those on other diabetes medications like gliptins.

Additionally, reduced cancer rates, longer survival, and fewer instances of metastasis were observed with GLP-1 usage in cases of endometrial, bladder, and prostate cancers, along with small intestine and blood cancers.

A separate analysis from community oncology practices in the U.S. revealed improved overall survival rates for GLP-1 users across various tumor types, translating to about a one-third reduction in mortality risk.

Interestingly, cancer patients undergoing immunotherapy appeared to benefit more when also taking GLP-1 drugs, suggesting they might interact favorably with the immune system.

For those with type 2 diabetes and advanced kidney disease, lower mortality and incidence rates of cancers such as lung and colorectal were significantly noted among GLP-1 users compared to non-users.

While there are warnings regarding potential thyroid cancer risks associated with GLP-1 medications based on animal studies, researchers emphasize these recent results hint at a broadly advantageous effect against various cancer types, rather than benefits limited to just a few cancers.

These medications were primarily developed for diabetes treatment but have also shown promise in reducing heart disease risks, improving sleep apnea, and addressing substance use issues.

Dr. Marcin Chwistek from the Fox Chase Cancer Center pointed out that these drugs never really functioned solely as glucose-lowering agents.

Considerations and Limitations

Researchers did highlight that most evidence shared comes from observational studies. This brings potential confounding factors into play, as patients on GLP-1 drugs may have other health differences that could skew results.

While efforts were made to account for these disparities, it’s important to note that these studies can’t definitively prove that GLP-1s enhance cancer outcomes. Further trials are needed to determine their specific benefits when combined with standard cancer treatments.

The beneficial cancer effects observed weren’t solely linked to weight loss, indicating other factors are at work here.

In a separate long-term study involving nearly 120,000 participants, GLP-1 medications showed a lower incidence of new prostate cancer diagnoses in high-risk men compared to other drugs like Propecia and Avodart.

Dr. Colton Jones from the University of Texas San Antonio Mays Cancer Center, who presented at the ASCO meeting, noted that GLP-1 users only experienced a slight weight reduction after a year. He speculated that both weight loss and direct anti-cancer and anti-inflammatory effects could explain the associations found in their study.

Dr. Chwistek remarked on the longstanding indications that GLP-1s might have broader implications due to their anti-inflammatory properties. He emphasized the consistent results across various cancers in one of the largest studies, suggesting that this warrants further investigation through prospective randomized trials.